Pannexin Channel Inhibition: An Evolving Target to Lower Blood Pressure?

Pannexin Channel Inhibition: An Evolving Target to Lower Blood Pressure?

More than 50 years after spironolactone has come on the market its mechanism of action continues to expand. In this issue of Circulation Research , Good et al. document the discovery that spironolactone is not only an inhibitor of the mineralocorticoid receptor, but also inhibits pannexin 1 channels...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation research 2018-02, Vol.122 (4), p.543-545
1. Verfasser: Huke, Sabine
Format: Artikel
Sprache:eng
Schlagworte:
Aldosterone
Antihypertensive Agents
Blood Pressure - drug effects
Mineralocorticoid Receptor Antagonists
Spironolactone
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:More than 50 years after spironolactone has come on the market its mechanism of action continues to expand. In this issue of Circulation Research , Good et al. document the discovery that spironolactone is not only an inhibitor of the mineralocorticoid receptor, but also inhibits pannexin 1 channels.
ISSN:0009-7330
1524-4571
DOI:10.1161/CIRCRESAHA.118.312566